CSIRO, opens a new lab that will supercharge Australia’s ability to produce vaccines and therapeutics locally
Posted: 11 August 2022 CSIRO, Australia’s national science agency, has opened a new $23.1 million national lab in Melbourne that will bolster the nation’s ability to produce vaccines and drug treatments onshore. Researchers at CSIRO’s National Vaccine and…
Research Australia’s Global Landscape Analysis of Childhood Dementia Research
Posted: 10 August 2022 Research Australia is pleased to partner with the Childhood Dementia Initiative to report on global childhood dementia clinical research: Childhood Dementia Global Landscape Analysis. Research Australia’s report identifies high value-research investment opportunities and emerging…
Genesis Capital invests in Australian firm Crux Biolabs
Posted: 9 August 2022 Genesis Capital is partnering with existing management to expand Crux into new testing and clinical trial streams. Crux Biolabs, a leading Australian laboratory for vaccines, immunotherapies, immuno-oncology and infectious diseases, has announced a significant…
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
Posted: 8 August 2022 Neuren Pharmaceuticals (ASX: NEU) today announced that its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome (PMS) and Pitt Hopkins syndrome (PTHS) are open for enrolment. The first subjects…
Burnet teams up with Monash and BioCurate to develop novel HIV antivirals
Posted: 4 August 2022 Burnet Institute, in collaboration with Monash Institute of Pharmaceutical Sciences (MIPS) has received Proof of Concept funding from BioCurate to develop next-generation human immunodeficiency virus (HIV) antivirals. The multi-disciplinary research team, led jointly by…
Breakthrough Victoria announces investment in Seer, powering global expansion
Posted: 25 July 2022 Breakthrough Victoria has announced recently its investment in Victorian medical technology group Seer Medical to support its plan to become a global leader in epilepsy home monitoring and management. Seer is globally renowned as…
NHMRC consultation on options to reach gender equity in the Investigator Grant scheme
Posted: 21 June 2022 The NHMRC has released a discussion paper presenting some options to reach gender equity in the Investigator Grant scheme. There will be a series of eight open forums held in Queensland, New South Wales,…
Acadia submits Rett Syndrome New Drug Application to the FDA
Posted: 19 July 2022 Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) is pleased to report that its US partner Acadia Pharmaceuticals (Nasdaq: ACAD) has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for…
ANDHealth extends partnership with Therapeutic Goods Administration to accelerate digital health regulatory adoption and commercialisation
Posted: July 18 2022 ANDHealth, Australia’s leading digital health commercialisation organisation, has announced the extension of its partnership with the Therapeutic Goods Administration (TGA) to support Australia’s fast-growing digital health sector. The extended partnership will see TGA fund…
Advertising of Therapeutic Goods in Australia – Are your advertising campaigns compliant? – Stephens Lawyers & Consultants
Posted: 23 June 2022 Advertising compliance for therapeutic goods in Australia is complex, requiring one to remain up-to-date on a number of different advertising laws which are administered by different regulators. This article provides a timely reminder that as…
First harvest at medicinal cannabis facility near Mildura in Victoria’s north-west
Posted: 16 June 2022 Key points: The first crop has been harvested from a medicinal cannabis facility built in a former fruit juice factory near Mildura Cann Group received approval to cultivate the crop at the $115 million…
Immutep’s TACTI-002 trial meets primary endpoint in lung cancer
Posted: 6 June 2022 Immutep reports positive Overall Response Rate in its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients…
